Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French Innovative Leukemia Organisation
• Collaborator: Amgen

Criteria

Inclusion Criteria:

• patients aged from 15 to 60 years

• previously untreated

• histologically proven aggressive NHL

• high aa-IPI (equal to 3)

• proper underlying organ function

Exclusion Criteria:

• transformed low-grade, lymphoblastic, mantle-cell, or Burkitt's lymphoma